May 1, 2024New England Journal of Medicine

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

View Full Paper

Ask AI

Bookmark

Authors

MSMarie ScullyUniversity College Hospital AAAna G. AntunEmory University SCSpero R. CatalandThe Ohio State University Wexner Medical Center

Discussion

Member takes

Implication

Clinical investigation evaluates recombinant ADAMTS13 against standard plasma therapy in congenital thrombotic thrombocytopenic purpura, highlighting unmet treatment needs.

Key Points

Efficacy and safety profiles of recombinant ADAMTS13 remain unestablished compared to routine plasma-derived products for managing congenital thrombotic thrombocytopenic purpura.
Standard therapy relies entirely on plasma-derived products, yet clinical outcomes under routine prophylaxis or on-demand treatment require systematic, targeted investigation.
Analysis of congenital thrombotic thrombocytopenic purpura highlights critical gaps in safety and therapeutic efficacy between recombinant ADAMTS13 and standard plasma therapy.

Cite This Study

Scully et al. (2024) studied this question.

synapsesocial.com/papers/68e6c02bb6db64358763f48b https://doi.org/10.1056/nejmoa2314793

View Full Paper

Ask AI

Bookmark

Implication

Clinical investigation evaluates recombinant ADAMTS13 against standard plasma therapy in congenital thrombotic thrombocytopenic purpura, highlighting unmet treatment needs.

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Discussion

Member takes

Implication

Key Points

Cite This Study

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider